The 12 Best Income Investments for 2023, According to Barron’s

While it might not be a feast now for income-oriented investors, it’s a lot better than the famine that prevailed for much of the past decade. Yields on a range of bond and bond-related investments ro...

The Best Income Investing Ideas for 2023

While it might not be a feast now for income-oriented investors, it’s a lot better than the famine that prevailed for much of the past decade. Yields on a range of bond and bond-related investments ro...

Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Clovis Oncology Inc., maker of the ovarian and prostate cancer drug Rubraca, filed for bankruptcy over the weekend with a proposed deal in hand to sell its rights to a cancer therapy under development...

Novartis Looks Appealing, Based on Drug Pipeline and Planned Spinoff

Text size These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the vi...

Novartis Will Cut 8,000 Jobs Under CEO’s Shake-Up Plan

Text size Vasant Narasimhan, CEO of Novartis. ERIC PIERMONT/AFP/Getty Images Pharmaceutical giant Novartis said Tuesday it will lay off more than 7% of its workforce, just a few months after CEO Vas N...

Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn’t Happening.

Text size Late last year, Barron’s predicted a wave of deals, citing biotech companies’ cash holdings. Above, the plates used to print one-dollar bills. Alex Wong/Getty Images With biotech...